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ABSTRACT
Background. Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT)
in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces
fibroblast growth factor 23 (FGF23), but the mechanisms are unknown.
Methods. To investigate potential mediators of etelcalcetide-induced FGF23 reduction, we performed secondary analyses of
the 26-week randomized trials that compared the effects on PTH of etelcalcetide (n¼509) versus placebo (n¼514) and
etelcalcetide (n¼340) versus cinacalcet (n¼343) in adults with sHPT receiving hemodialysis. We analyzed changes in FGF23
in relation to changes in PTH, calcium, phosphate and bone turnover markers. We also investigated how concomitant
treatments aimed at mitigating hypocalcemia altered the FGF23-lowering effects of etelcalcetide.
Results. Etelcalcetide reduced FGF23 [median % change (quartile 1–quartile 3)] from baseline to the end of the trial
significantly more than placebo [–56% (–85 to –7) versus þ2% (–40 to þ65); P<0.001] and cinacalcet [–68% (–87 to –26) versus –
41% (–76 to þ25); P<0.001]. Reductions in FGF23 correlated strongly with reductions in calcium and phosphate, but not with
PTH; correlations with bone turnover markers were inconsistent and of borderline significance. Increases in concomitant
vitamin D administration partially attenuated the FGF23-lowering effect of etelcalcetide, but increased dialysate calcium
concentration versus no increase and increased dose of calcium supplementation versus no increase did not attenuate the
FGF23-lowering effects of etelcalcetide.
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Conclusion. These data suggest that etelcalcetide potently lowers FGF23 in patients with sHPT receiving hemodialysis and
that the effect remains detectable among patients who receive concomitant treatments aimed at mitigating treatment-
associated decreases in serum calcium.
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INTRODUCTION
Circulating concentrations of fibroblast growth factor 23 (FGF23)
are markedly elevated in patients with advanced chronic kidney
disease (CKD) [1]. Increased FGF23 helps to maintain phosphate
homeostasis in progressive CKD by stimulating renal phosphate
excretion and suppressing circulating vitamin D levels, the lat-
ter of which promotes secondary hyperparathyroidism (sHPT)
[2–8]. Although these effects of FGF23 mitigate hyperphosphate-
mia [1, 2, 9], elevated FGF23 is independently associated with in-
creased risks of cardiovascular disease, infection, anemia and
mortality [10–14].
Current guidelines for management of disordered mineral
metabolism in patients receiving hemodialysis focus on achiev-
ing target concentrations of parathyroid hormone (PTH), cal-
cium and phosphate [15]. Multiple combinations of therapeutic
strategies are utilized, including dietary phosphate restriction,
calcium-based and noncalcium-based phosphate binders, vita-
min D preparations and calcimimetics [13, 16–22]. Different
therapeutic approaches to sHPT have differential effects on
FGF23. Cinacalcet tends to lower FGF23, vitamin D tends to in-
crease FGF23 and calcium- and noncalcium-based phosphate
binders have variable effects [13, 16, 23]. There are currently no
therapeutic drugs specifically approved to target elevated FGF23
in patients with any stage of CKD.
Etelcalcetide (Parsabiv, Amgen, Thousand Oaks, CA, USA) is
an intravenous calcimimetic recently approved for treatment of
sHPT in patients receiving hemodialysis. In randomized con-
trolled trials, etelcalcetide reduced PTH and FGF23 more than
placebo or cinacalcet when added to standard-of-care treat-
ment that included calcitriol or vitamin D analogs, phosphate
binders and calcium supplementation administered at the dis-
cretion of individuals’ primary nephrologists [24, 25]. We con-
ducted the current secondary analyses of these trials to further
investigate potential mediators of etelcalcetide-induced reduc-
tions in FGF23. We tested the associations among changes in
FGF23 and calcium, phosphate, PTH and markers of bone turn-
over and further tested whether concomitant changes in calci-
triol or vitamin D analogs, dialysate calcium concentration or
calcium supplementation altered the FGF23-lowering effects of
etelcalcetide.
MATERIALS ANDMETHODS
Study population
We assessed the effects of etelcalcetide and cinacalcet on circu-
lating concentrations of FGF23 in a post hoc pooled analysis of
Phase 3 trials that were designed to evaluate the efficacy of etel-
calcetide to achieve PTH 300 pg/mL [24, 25]. The trials were ap-
proved by institutional review boards at participating trial sites
and were conducted in accordance with the Declaration of
Helsinki. Adult patients with sHPT receiving hemodialysis were
randomized 1:1 to 26 weeks of treatment with etelcalcetide
(n¼ 509) versus placebo (n¼ 514) or etelcalcetide (n¼ 340) versus
cinacalcet (n¼ 343) added to the standard of care. All
participants provided written informed consent. Etelcalcetide
was administered intravenously at a starting dose of 5 mg three
times weekly after hemodialysis and cinacalcet was taken orally
at a starting dose of 30 mg/day. Etelcalcetide (and the corre-
sponding intravenous placebo) could be titrated in increments
of 2.5 or 5 mg and cinacalcet in increments of 30 mg (dose range
30–180 mg) at Weeks 5, 9, 13 and 17. With investigators blinded
to PTH concentrations throughout the trial, calcimimetics were
titrated by protocol using an interactive voice or web response
system up to a maximum of 15 mg of etelcalcetide per dialysis
session or 180 mg of cinacalcet per day to achieve target PTH
levels between 100 and 300 pg/mL. The median average weekly
calcimimetic doses during the efficacy assessment phase at
Weeks 20–26 was 15.0 mg for etelcalcetide and the median aver-
age daily cinacalcet dose was 51.4 mg [interquartile range (IQR)
26.4–80.4] [25]. Dialysate calcium concentrations and specific
types and doses of phosphate binders, calcium supplements
and vitamin D preparations could be adjusted by individual
investigators at their discretion. Due to difficulty in standardiz-
ing individual participants’ total calcium dose across the wide
range of binders and supplements prescribed by investigators,
we chose to dichotomize calcium supplementation into groups
that either received any increase or no increase based on a com-
parison of their average doses during the efficacy assessment
phase and their baseline doses. We used a similar strategy to di-
chotomize changes in vitamin D dose and dialysate calcium
concentration according to whether individuals received an in-
crease or no increase in these interventions.
Assays
Central laboratories (Covance Central Laboratory Services,
Indianapolis, IN, USA; Meyrin, Switzerland; and Singapore) mea-
sured intact PTH (immunometric assay; ADVIA Centaur PTH
Assay, Siemens Healthcare, Erlangen, Germany), calcium and
phosphate in real time throughout the trials and stored and an-
alyzed samples for measurements of intact FGF23 (Kainos ELISA
kit, Kainos Labs, Tokyo, Japan), bone-specific alkaline phospha-
tase (BSAP) and C-telopeptide (CTX) at baseline and at the be-
ginning of Week 27. Note that while treatment in both trials
was 26 weeks, the final laboratory values were obtained at the
beginning of Week 27. Albumin-corrected serum calcium is pre-
sented in all analyses.
Statistical analysis
Within the placebo-controlled trials, we stratified participants
into three groups of sHPT severity according to baseline PTH
(<600, 600–1000 and >1000 pg/mL) and investigated the effects
of etelcalcetide versus placebo on the change in PTH from base-
line to Week 27 within these groups. Within each PTH stratum
we determined the mean baseline calcium, phosphate, calcium
 phosphate product and FGF23 and the percent change from
baseline following treatment with etelcalcetide or placebo dur-
ing the efficacy assessment phase, which was Weeks 20–27.
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We compared the percent change in FGF23 from baseline to
Week 27 between etelcalcetide and placebo and etelcalcetide
and cinacalcet using Wilcoxon rank sum tests. We calculated
Pearson correlation coefficients for percent changes in FGF23,
BSAP and CTX from the baseline to Week 27 measurements; for
PTH, calcium, phosphate and calcium  phosphate, we calcu-
lated percent changes from baseline using the mean of all val-
ues during the efficacy assessment phase (Weeks 20–27). We
analyzed the effects of an increase versus no increase in vita-
min D dose, calcium supplementation and dialysate calcium
concentration on randomized treatment-associated changes in
FGF23 levels at Week 27 by testing the Spearman correlations of
the within-group changes in FGF23 among participants in
whom concomitant treatments were or were not increased. We
analyzed all available data without imputation. Statistical sig-
nificance was defined as P< 0.05 without adjusting for multiple
comparisons. All analyses were performed using SAS software
(SAS Institute, Cary, NC, USA).
Data-sharing agreement
There is a plan to share data. This may include deidentified indi-
vidual patient data for variables necessary to address the specific
research question in an approved data-sharing request; also re-
lated data dictionaries, study protocol, statistical analysis plan, in-
formed consent form and/or clinical study report. Data-sharing
requests relating to data in this article will be considered after the
publication date and (i) this product and indication (or other new
use) have been granted marketing authorization in both the USA
and Europe or (ii) clinical development discontinues and the data
will not be submitted to regulatory authorities. There is no end
date for eligibility to submit a data-sharing request for these data.
Qualified researchers may submit a request containing the re-
search objectives, the Amgen product(s) and Amgen study/studies
in scope, endpoints/outcomes of interest, statistical analysis plan,
data requirements, publication plan and qualifications of the
researcher(s). In general, Amgen does not grant external requests
for individual patient data for the purpose of reevaluating safety
and efficacy issues already addressed in the product labelling. A
committee of internal advisors reviews requests. If not approved,
then requests may be further arbitrated by a Data Sharing
Independent Review Panel. Requests that pose a potential conflict
of interest or an actual or potential competitive risk may be de-
clined at Amgen’s sole discretion and without further arbitration.
Upon approval, information necessary to address the
research question will be provided under the terms of a data-shar-
ing agreement. This may include anonymized individual patient
data and/or available supporting documents containing fragments
of analysis code where provided in analysis specifications. Further
details are available at https://www.amgen.com/science/clinical-
trials/clinical-data-transparency-practices/
RESULTS
Baseline data
Characteristics of the study population from the placebo-
controlled trial of etelcalcetide are presented in Table 1 overall
and according to baseline severity of sHPT, expressed in ascend-
ing strata of pretreatment PTH (<600, 600–1000 and >1000 pg/
mL). Participants in the highest PTH stratum had the highest
baseline serum concentrations of calcium, phosphate and
FGF23 while the dose of calcitriol or vitamin D analogs at base-
line was similar across strata (Table 1).
Postrandomization data
The mean percent reduction in PTH with etelcalcetide treat-
ment was similar regardless of baseline sHPT severity, ranging
from –54% [95% confidence interval (CI) –59 to –50], to –58% (95%
CI –62 to –54), to –55% (95% CI –62 to –49) from the lowest to the
highest baseline PTH strata, despite the progressive increase in
delivered dose of etelcalcetide across the ascending PTH strata
(Table 2). In the full study populations, etelcalcetide decreased
FGF23 from baseline to Week 27 significantly more than placebo
[–56% (95% CI –85 to –7) versus þ2% (–40 to þ65); P< 0.001;
Figure 1A] and significantly more than cinacalcet [–68% (95% CI
–87 to –26) versus –41% (–76 to þ25); P< 0.001; Figure 1B].
Although patients in the highest baseline PTH stratum in the
placebo-controlled trial had the largest relative reduction in cal-
cium, phosphate and FGF23 induced by etelcalcetide (Table 2),
etelcalcetide (and cinacalcet)-induced reductions in FGF23 cor-
related strongly with concomitant reductions in calcium, phos-
phate and calcium  phosphate product, but not with changes
in PTH (Table 3); changes in bone markers were less strongly
correlated with change in FGF23.
Effects of concomitant treatments
Etelcalcetide significantly decreased FGF23 compared with pla-
cebo, irrespective of whether the dose of vitamin D was in-
creased (between-group comparisons; Figure 2A), but within the
etelcalcetide group, the effect on FGF23 was partially attenuated
among participants who received an increase versus no in-
crease in their dose of calcitriol or vitamin D analog (median
change –48% versus –62%; P¼ 0.045). In the active-controlled tri-
als (Figure 2B), etelcalcetide decreased FGF23 significantly more
than cinacalcet among participants whose calcitriol or vitamin
D analog dose was not increased (–71% versus –41%; P< 0.001),
but there was no significant difference among those in whom
the calcitriol or vitamin D analog dose was increased (–60% ver-
sus –42%; P¼ 0.07); similar to the placebo-controlled trials, the
etelcalcetide effect on FGF23 was partially attenuated among
participants who received an increase versus no increase in
their dose of calcitriol or vitamin D analog (–60% versus –71%;
P¼ 0.004; Figure 2B). Etelcalcetide decreased FGF23 significantly
more than placebo or cinacalcet regardless of whether dialysate
calcium or calcium supplementation was increased (between-
group comparisons; Figures 3 and 4). Compared with no in-
crease, an increase in dialysate calcium concentration did not
attenuate the FGF23-lowering effects of etelcalcetide in the
placebo-controlled trials (–55% versus –57%; P¼ 0.68; Figure 3A)
and was associated with significantly more FGF23 reduction in
the active-controlled trials (–82% versus –66%; P¼ 0.02;
Figure 3B). Likewise, compared with no increase, an increase in
dose of calcium supplementation did not attenuate the FGF23-
lowering effects of etelcalcetide in the placebo-controlled trials
(–59% versus –53%; P¼ 0.24; Figure 4A) and was associated with
significantly more FGF23 reduction in the active-controlled tri-
als (–76% versus –64%; P¼ 0.03; Figure 4B).
DISCUSSION
This secondary analysis of etelcalcetide clinical trials offers new
evidence relevant to our understanding of the pathogenesis and
management of sHPT in patients receiving hemodialysis.
Etelcalcetide markedly reduced FGF23 concentrations compared
with placebo and also more than cinacalcet. The magnitude of
the FGF23-lowering effect was largest among patients with the
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most severe sHPT at baseline, marked by their having the high-
est pretreatment PTH, calcium, phosphate and FGF23.
Nevertheless, the degree of etelcalcetide-induced FGF23 reduc-
tion was most strongly associated with concomitant changes in
calcium and phosphate rather than the change in PTH, which
was reduced to a similar extent by etelcalcetide regardless of its
baseline concentration.
The complex regulation of FGF23 in CKD involves competing
effects of multiple intrinsic physiological factors and exogenous
treatments. High serum concentrations of PTH, calcium and
phosphate and reduced renal expression of Klotho each stimu-
late increases in FGF23 [6, 13, 26–32]. Therapeutically, phos-
phate binders can lower FGF23, presumably by reducing the
total absorbed phosphate load; however, the effect depends on
the type of binder. Whereas iron-based and other noncalcium-
based binders lowered FGF23 in some but not all studies [33–36],
calcium-based binders appear to raise FGF23 because calcium
loading directly stimulates FGF23 independent of serum phos-
phate and despite calcium-induced lowering of PTH [37, 38].
PTH-lowering therapies also differ in their effects on FGF23.
Activated vitamin D and its analogs stimulate FGF23 via direct
effects on the vitamin D response element of the FGF23 gene
promoter [3, 13] and perhaps also indirectly via increases in se-
rum calcium and phosphate. In contrast, for a comparable
magnitude of PTH reduction as activated vitamin D, calcimi-
metics lower FGF23, but the mechanisms are unknown [13, 16,
19, 22, 23].
One of the primary aims of this study was to investigate the
potential mediators through which calcimimetics reduce
FGF23. The candidate factors we examined included PTH, cal-
cium, phosphate and bone turnover markers. While PTH, cal-
cium and phosphate were associated with baseline FGF23,
etelcalcetide-mediated reductions in FGF23 were associated
with reductions of calcium, phosphate and calcium  phos-
phate product, but, remarkably, not with changes in PTH; asso-
ciations of FGF23 reduction with markers of bone turnover
were of borderline and inconsistent significance. The signfi-
cant relations among changes in FGF23 with changes in cal-
cium, phosphate and calcium  phosphate could be
interpreted as suggesting that osteocytes may respond to total
mineral ion load. This is supported by synergistic stimulation
of FGF23 by calcium and phosphate in a double knockout
mouse lacking both PTH and the calcium-sensing receptor [39–
41]. The lack of association between PTH reduction and
changes in FGF23 in the current analysis is also consistent with
prior studies of cinacalcet in which reductions in FGF23 were
unrelated to changes in PTH, but instead correlated with
changes in calcium and phosphate [20, 22]. Furthermore, in
patients receiving dialysis who underwent subtotal parathy-
roidectomy, which acutely and drastically reduces PTH, post-
operative decreases in FGF23 were most closely related to
changes in calcium  phosphate product [42]. In another study
of total parathyroidectomy, FGF23 changed minimally in
patients who were treated postoperatively with calcitriol and
calcium to maintain serum calcium [43].
In aggregate, these data suggest that calcium and phosphate
are more important drivers of calcimimetic-induced FGF23 re-
duction than PTH or bone turnover markers. However, alterna-
tive interpretations are also possible. For example, more
biological variability in PTH versus calcium and phosphate and
more laboratory imprecision in PTH assays relative to calcium
and phosphate assays might have obscured a relation between
the magnitude of PTH and FGF23 reduction. In support of this
hypothesis, the highest PTH stratum did experience the greatestT
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magnitude of FGF23 reduction (although this group also had the
largest variations in serum calcium and phosphate). While it is
presumed that PTH reduction is the mediator of etelcalcetide-
induced reductions in calcium and phosphate, varying degrees
of PTH resistance at the level of bone might also blur the rela-
tion between changes in PTH and changes in FGF23 [10, 27].
There also remains the possibility that calcimimetics might in-
fluence calcium and phosphate homeostasis (or FGF23 directly)
via PTH-independent mechanisms mediated by direct effects
on bone cells and bone turnover. Although the association with
bone turnover markers was weak, this mechanism is plausible
given that an investigational calcimimetic (AMG641) affected
bone turnover in a uremic thyro-parathyroidectomized rat
model in which PTH levels were maintained at a constant level
by PTH infusion [44]. Finally, it is possible that while PTH is an
important basal regulator of FGF23 [6, 26–29], its effects might
be overwhelmed by concomitant changes in calcium and phos-
phate in the presence of a potent calcimimetic.
The second major aim of this study was to investigate the
extent to which treatments that mitigate etelcalcetide-induced
hypocalcemia might also lessen its efficacy to reduce FGF23 lev-
els. In the trials, investigators were blinded to treatment and
PTH levels but were able to monitor serial serum calcium levels
for safety reasons. Treatment of calcium reduction was allow-
able but not mandated unless calcium decreased to <7.5 mg/dL
or the patient developed symptomatic hypocalcemia. Potential
interventions could include starting or increasing doses of
calcitriol or vitamin D analogs, calcium supplements and
calcium-based binders or increasing the dialysate calcium con-
centration. Overall, etelcalcetide reduced FGF23 by a median of
47%, regardless of whether participants underwent simulta-
neous increases in their doses of vitamin D. In contrast, etelcal-
cetide unexpectedly reduced FGF23 more in patients whose
doses of calcium supplements or dialysate calcium increased—
at least 52% and as high as 82%. This might have occurred be-
cause patients who required calcium-raising interventions were
likely those who had the largest reductions in serum calcium,
and thus FGF23, in response to etelcalcetide. These results have
potentially important clinical implications. They suggest that if
FGF23 reduction is advanced as a therapeutic goal in the future,
use of etelcalcetide could be a potent therapeutic. While etelcal-
cetide is associated with high rates of hypocalcemia by virtue of
its known mechanism of action to suppress PTH, our data sug-
gest that ancillary treatments to abrogate symptomatic hypo-
calcemia will not fully offset the FGF23-lowering effects of
etelcalcetide.
FIGURE 1: Changes in FGF23 in the randomized controlled trials of (A) etelcalcetide versus placebo and (B) etelcalcetide versus cinacalcet. Median percent change (quar-
tile 1, quartile 3) ¼median percent change from baseline to Week 27.
Table 3. Pearson correlations coefficients between percent changes in FGF23 and other bone mineral markers
Bone mineral markers Placebo-controlled Head-to-head
Etelcalcetide Placebo Etelcalcetide Cinacalcet
PTH –0.08 0.01 –0.02 0.13
Calcium 0.52 0.06 0.46 0.34
Phosphate 0.34 0.48 0.56 0.51
Calcium  phosphate 0.61 0.50 0.66 0.60
Bone-specific alkaline phosphatase –0.23 –0.27 –0.17 –0.15
Collagen type I cross-linked C-telopeptide –0.11 0.00 –0.02 0.02
Bold numbers connote statistical significance of P<0.01.
FGF23¼fibroblast growth factor-23; PTH, parathyroid hormone.
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The strengths of this study include its large and diverse clin-
ical trial populations, frequent central measurements of PTH,
calcium, phosphate and markers of bone turnover and protocol-
directed titration of the interventions. In addition to these
strengths, certain limitations may influence our interpretation
of the data. Although PTH, calcium and phosphate were
assessed at several points throughout the trials, we only mea-
sured FGF23 at baseline and at Week 27. It is also unclear how
the results would have differed had we included a population
with shorter dialysis vintage and less severe sHPT at baseline.
Due to the complexity of standardizing individual patients’ total
calcium dose across the multiple different preparations they
could have received, we chose to dichotomize calcium supple-
mentation and the other concomitant medications into two
groups defined by whether their dose was or was not increased
during follow-up. As a result, we could not perform more nu-
anced investigations of potential dose-dependent effects of
these treatments, which are needed. Furthermore, use of con-
comitant calcium-raising therapies were not randomized or ad-
ministered by protocol, which further limits inferences that can
be drawn from the concomitant treatment analyses. However,
variability in the use of these strategies to raise serum calcium
FIGURE 2: Changes in FGF23 according to concomitant vitamin D treatment in trials of (A) etelcalcetide versus placebo and (B) etelcalcetide versus cinacalcet. Median
percent change (quartile 1–quartile 3) ¼median percent change from baseline to Week 27. Spearman correlation coefficients (r) and P-values on the figure panels sum-
marize and compare the within-group associations between percent change from baseline to Week 27 in FGF23 according to whether vitamin D dose was or was not in-
creased. Results below the figure panels summarize between-group comparisons stratified by the change in vitamin D dosing.
FIGURE 3: Changes in FGF23 according to concomitant increases in dialysate calcium concentration in trials of (A) etelcalcetide versus placebo and (B) etelcalcetide ver-
sus cinacalcet. Median (quartile 1, quartile 3) ¼median percent change from baseline to week 27. Spearman correlation coefficients (r) and P-values on the figure panels
summarize and compare the within-group associations between percent change from baseline to Week 27 in FGF23 according to whether dialysate calcium was or was
not increased. Results below the figure panels summarize between-group comparisons stratified by the change in dialysate calcium.
Etelcalcetide reduces FGF23 in sHPT | 81
enabled our hypothesis-generating analyses that otherwise
would have been limited had these strategies been tightly regu-
lated by protocol rather than at the discretion of investigators.
The evaluation of changes in FGF23 was a prespecified ex-
ploratory analysis of the placebo-controlled and active-
controlled etelcalcetide clinical trials, but the studies were not
primarily designed to explore the effect of etelcalcetide on
FGF23. We speculate that etelcalcetide could induce even more
pronounced reductions in FGF23 if drug titration were moti-
vated by FGF23 rather than PTH targets. Since our results fo-
cused only on biochemical endpoints, additional studies are
also needed to determine the effect on clinical outcomes of
etelcalcetide-induced reduction in FGF23.
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